Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains
Open Access
- 1 July 2002
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 3 (3) , 200-206
- https://doi.org/10.1046/j.1468-1293.2002.00116.x
Abstract
Objective Drug resistant HIV strains can be identified by genotypic analysis. The prediction of resistance from the HIV pol sequence, however, requires expert interpretation which is currently provided by various interpretation programs. In the present study, the comparability of two of these programs was investigated. Methods One hundred and six HIV sequences obtained from patient samples were subjected to interpretation by the Stanford HIV‐SEQ program (http://hivdb.stanford.edu) and, in parallel, by virtual phenotype analysis (VircoNET TM). Results The overall concordance between the two assays was high with respect to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors. Highly discrepant results were obtained from 22 samples (1.5% of all comparisons), and these discrepancies were significantly associated with the interpretation of nucleoside reverse transcriptase inhibitors (NRTIs) (P < 0.01), especially regarding resistance to zalcitabine (ddC), didanosine (ddI) and abacavir (ABC). Nearly all of these discrepant samples showed a sensitive virtual phenotype. Mutations at codons 69 and 74 were associated with a discrepant interpretation for ddC. Conclusions The prediction of resistance to certain NRTIs from a given HIV sequence may be contradictory and requires further investigation.Keywords
This publication has 17 references indexed in Scilit:
- Performance of the Applied Biosystems ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Sequence-Based Analysis of HIV-1 in Pediatric Plasma SamplesJournal of Clinical Microbiology, 2001
- Phenotypic and Genotypic Resistance Assays: Methodology, Reliability, and InterpretationsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European settingAIDS, 2001
- Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.Journal of Antimicrobial Chemotherapy, 1998
- The development of resistance of HIV-1 to zalcitabineAIDS, 1997
- Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral TherapyAnnals of Internal Medicine, 1995
- Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidineAntimicrobial Agents and Chemotherapy, 1992
- Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse TranscriptaseScience, 1991
- Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapyThe Lancet, 1990
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989